

Marlys L Koschinsky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3661305/publications.pdf>

Version: 2024-02-01

89
papers

5,988
citations

81900
39
h-index

71685
76
g-index

89
all docs

89
docs citations

89
times ranked

4664
citing authors

#	ARTICLE	IF	CITATIONS
1	Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress. <i>Cell Metabolism</i> , 2010, 12, 467-482.	16.2	397
2	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624.	1.6	396
3	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	2.8	337
4	Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. <i>Journal of Clinical Lipidology</i> , 2019, 13, 374-392.	1.5	315
5	Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, ATV0000000000000147.	2.4	207
6	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. <i>Circulation</i> , 2019, 139, 1472-1482.	1.6	196
7	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2150-2162.	2.8	187
8	Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve. <i>Circulation</i> , 2015, 132, 677-690.	1.6	185
9	Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?. <i>Journal of Lipid Research</i> , 2016, 57, 745-757.	4.2	181
10	Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. <i>Journal of Biological Chemistry</i> , 2015, 290, 11649-11662.	3.4	176
11	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). <i>Journal of Lipid Research</i> , 2013, 54, 2815-2830.	4.2	174
12	Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019, 16, 305-318.	13.7	158
13	A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2030-2036.	2.4	143
14	Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells. <i>Biochemistry</i> , 1991, 30, 5044-5051.	2.5	137
15	Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. <i>Clinical Biochemistry</i> , 2004, 37, 333-343.	1.9	134
16	Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. <i>FASEB Journal</i> , 2006, 20, 559-561.	0.5	111
17	Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. <i>Current Opinion in Lipidology</i> , 2004, 15, 167-174.	2.7	110
18	Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity. <i>FASEB Journal</i> , 1998, 12, 1765-1776.	0.5	100

#	ARTICLE	IF	CITATIONS
19	Inhibition of Plasminogen Activation by Lipoprotein(a). <i>Journal of Biological Chemistry</i> , 2003, 278, 23260-23269.	3.4	99
20	Lipoprotein(a). <i>Current Opinion in Lipidology</i> , 2012, 23, 133-140.	2.7	99
21	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359.	4.5	96
22	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). <i>Journal of Lipid Research</i> , 2015, 56, 2273-2285.	4.2	85
23	Characterization of the Gene Encoding Human TAFI (Thrombin-Activable Fibrinolysis Inhibitor; Plasma) Tj ETQq1 1 0,784314 rgBT /Overl	2.5	84
24	CC Chemokine I-309 Is the Principal Monocyte Chemoattractant Induced by Apolipoprotein(a) in Human Vascular Endothelial Cells. <i>Circulation</i> , 2000, 102, 786-792.	1.6	84
25	Lipoprotein(a) Assembly. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1559-1567.	2.4	76
26	Mechanisms of Lipoprotein(a) Pathogenicity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1550-1551.	2.4	73
27	Apolipoprotein(a) Enhances Platelet Responses to the Thrombin Receptor-Activating Peptide SFLLRN. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1998, 18, 1393-1399.	2.4	68
28	Lipoprotein(a) Concentration and Apolipoprotein(a) Size. <i>Circulation</i> , 1999, 100, 1151-1153.	1.6	68
29	Lipoprotein(a) Is Associated Differentially With Carotid Stenosis, Occlusion, and Total Plaque Area. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 1851-1856.	2.4	66
30	Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1426-1437.	2.8	64
31	The renaissance of lipoprotein(a): Brave new world for preventive cardiology?. <i>Progress in Lipid Research</i> , 2017, 68, 57-82.	11.6	63
32	Analysis of the Proteolytic Activity of a Recombinant Form of Apolipoprotein(a). <i>Biochemistry</i> , 1995, 34, 15777-15784.	2.5	59
33	Antifibrinolytic Effect of Recombinant Apolipoprotein(a) in Vitro Is Primarily Due to Attenuation of tPA-Mediated Glu-Plasminogen Activation. <i>Biochemistry</i> , 1995, 34, 5151-5157.	2.5	57
34	The Apolipoprotein(a) Component of Lipoprotein(a) Stimulates Actin Stress Fiber Formation and Loss of Cell-Cell Contact in Cultured Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 6526-6533.	3.4	55
35	Sequences within Apolipoprotein(a) Kringle IV Types 6-8 Bind Directly to Low-Density Lipoprotein and Mediate Noncovalent Association of Apolipoprotein(a) with Apolipoprotein B-100. <i>Biochemistry</i> , 1998, 37, 7892-7898.	2.5	54
36	Apolipoprotein(a), through Its Strong Lysine-binding Site in KIV10, Mediates Increased Endothelial Cell Contraction and Permeability via a Rho/Rho Kinase/MYPT1-dependent Pathway. <i>Journal of Biological Chemistry</i> , 2008, 283, 30503-30512.	3.4	54

#	ARTICLE	IF	CITATIONS
37	Inhibition of plasminogen activation by apo(a): role of carboxyl-terminal lysines and identification of inhibitory domains in apo(a). <i>Journal of Lipid Research</i> , 2014, 55, 625-634.	4.2	52
38	The Solution Phase Interaction between Apolipoprotein(a) and Plasminogen Inhibits the Binding of Plasminogen to a Plasmin-Modified Fibrinogen Surface. <i>Biochemistry</i> , 1997, 36, 10353-10363.	2.5	50
39	Apolipoprotein(a) Attenuates Endogenous Fibrinolysis in the Rabbit Jugular Vein Thrombosis Model In Vivo. <i>Circulation</i> , 1997, 96, 1612-1615.	1.6	42
40	Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. <i>Current Atherosclerosis Reports</i> , 2005, 7, 389-395.	4.8	41
41	Activation of liver X receptor attenuates lysophosphatidylcholine-induced IL-8 expression in endothelial cells via the NF- κ B pathway and SUMOylation. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2249-2258.	3.6	40
42	Development of an LC-MS/MS Proposed Candidate Reference Method for the Standardization of Analytical Methods to Measure Lipoprotein(a). <i>Clinical Chemistry</i> , 2021, 67, 490-499.	3.2	40
43	Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9. <i>PLoS ONE</i> , 2017, 12, e0180869.	2.5	40
44	New Frontiers in Lp(a)-Targeted Therapies. <i>Trends in Pharmacological Sciences</i> , 2019, 40, 212-225.	8.7	39
45	Identification of a Critical Lysine Residue in Apolipoprotein B-100 That Mediates Noncovalent Interaction with Apolipoprotein(a). <i>Journal of Biological Chemistry</i> , 2001, 276, 36155-36162.	3.4	37
46	Plasminogen promotes cholesterol efflux by the ABCA1 pathway. <i>JCI Insight</i> , 2017, 2, .	5.0	36
47	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. <i>Journal of Lipid Research</i> , 2019, 60, 2082-2089.	4.2	35
48	Quantitative Evaluation of the Contribution of Weak Lysine-binding Sites Present within Apolipoprotein(a) Kringle IV Types 6-8 to Lipoprotein(a) Assembly. <i>Journal of Biological Chemistry</i> , 2004, 279, 2679-2688.	3.4	33
49	Novel Insights Into Lp(a) Physiology and Pathogenicity: More Questions Than Answers?. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2006, 6, 267-278.	0.7	33
50	High-resolution crystal structure of apolipoprotein(a) kringle IV type 7: Insights into ligand binding. <i>Protein Science</i> , 2001, 10, 1124-1129.	7.6	32
51	Oxidized phospholipid modification of lipoprotein(a): Epidemiology, biochemistry and pathophysiology. <i>Atherosclerosis</i> , 2022, 349, 92-100.	0.8	31
52	Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1358-1366.	1.5	30
53	Carboxyl-terminal truncation of apolipoprotein B100 inhibits lipoprotein(a) particle formation. <i>FEBS Letters</i> , 1994, 350, 77-81.	2.8	27
54	Stimulation of Vascular Smooth Muscle Cell Proliferation and Migration by Apolipoprotein(a) Is Dependent on Inhibition of Transforming Growth Factor- β 2 Activation and on the Presence of Kringle IV Type 9. <i>Journal of Biological Chemistry</i> , 2004, 279, 55187-55195.	3.4	27

#	ARTICLE	IF	CITATIONS
55	Lipoprotein(a). <i>Endocrinology and Metabolism Clinics of North America</i> , 2014, 43, 949-962.	3.2	27
56	Catalysis of Covalent Lp(a) Assembly: Evidence for an Extracellular Enzyme Activity that Enhances Disulfide Bond Formation. <i>Biochemistry</i> , 2006, 45, 9919-9928.	2.5	23
57	Pathobiology of Lp(a) in calcific aortic valve disease. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 797-807.	1.5	23
58	Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a). <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2021, 28, 159-173.	2.3	22
59	Comparative Analyses of the Lysine Binding Site Properties of Apolipoprotein(a) Kringle IV Types 7 and 10. <i>Biochemistry</i> , 2002, 41, 1149-1155.	2.5	21
60	Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2018, 55, 33-54.	6.1	20
61	Global think tank on the clinical considerations and management of lipoprotein(a): The top questions and answers regarding what clinicians need to know. <i>Progress in Cardiovascular Diseases</i> , 2022, 73, 32-40.	3.1	19
62	Analysis of the mechanism of lipoprotein(a) assembly. <i>Clinical Genetics</i> , 1997, 52, 338-346.	2.0	17
63	Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2022, 42, 289-304.	2.4	17
64	Lipoprotein(a) as a therapeutic target in cardiovascular disease. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 747-757.	3.4	16
65	Identification of Sequences in Apolipoprotein(a) that Maintain Its Closed Conformation: A Novel Role for Apo(a) Isoform Size in Determining the Efficiency of Covalent Lp(a) Formation. <i>Biochemistry</i> , 2004, 43, 9978-9988.	2.5	15
66	Interaction of Autotaxin With Lipoprotein(a) in Patients With Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2020, 5, 888-897.	4.1	15
67	Baboon Lipoprotein(a) Binds Very Weakly to Lysine Agarose and Fibrin Despite the Presence of a Strong Lysine-Binding Site in Apolipoprotein(a) Kringle IV Type 10. <i>Biochemistry</i> , 2005, 44, 555-564.	2.5	14
68	Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis. <i>Metabolites</i> , 2021, 11, 459.	2.9	14
69	Lipoprotein(a): Expanding our knowledge of aortic valve narrowing. <i>Trends in Cardiovascular Medicine</i> , 2021, 31, 305-311.	4.9	13
70	Pathophysiology and Risk of Atrial Fibrillation Detected after Ischemic Stroke (PARADISE): A Translational, Integrated, and Transdisciplinary Approach. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 606-619.	1.6	12
71	Understanding the ins and outs of lipoprotein (a) metabolism. <i>Current Opinion in Lipidology</i> , 2022, 33, 185-192.	2.7	12
72	The journey towards understanding lipoprotein(a) and cardiovascular disease risk: are we there yet?. <i>Current Opinion in Lipidology</i> , 2018, 29, 259-267.	2.7	11

#	ARTICLE	IF	CITATIONS
73	A Comparative Analysis of the Lipoprotein(a) and Low-Density Lipoprotein Proteomic Profiles Combining Mass Spectrometry and Mendelian Randomization. <i>CJC Open</i> , 2021, 3, 450-459.	1.5	11
74	Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. <i>Hepatology</i> , 2017, 65, 1851-1864.	7.3	10
75	Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen on the surface of vascular endothelial and smooth muscle cells. <i>Thrombosis Research</i> , 2018, 169, 1-7.	1.7	8
76	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). <i>Journal of Lipid Research</i> , 2020, 61, 1263-1270.	4.2	8
77	Therapeutic Lowering of Lipoprotein(a). <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002052.	3.6	6
78	Inhibition of pericellular plasminogen activation by apolipoprotein(a): Roles of urokinase plasminogen activator receptor and integrins $\alpha 2$ and $\alpha 3$. <i>Atherosclerosis</i> , 2018, 275, 11-21.	0.8	6
79	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2019, 30, 428-437.	2.7	6
80	Sortilin enhances secretion of apolipoprotein(a) through effects on apolipoprotein B secretion and promotes uptake of lipoprotein(a). <i>Journal of Lipid Research</i> , 2022, 63, 100216.	4.2	4
81	Lipoprotein(a) and the link between atherosclerosis and thrombosis. <i>Canadian Journal of Cardiology</i> , 2004, 20 Suppl B, 37B-43B.	1.7	3
82	Genetics to the Rescue. <i>Journal of the American College of Cardiology</i> , 2021, 78, 450-452.	2.8	2
83	Angelo Scanu Memorial. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1245-1246.	2.4	0
84	Lipoprotein(a). , 2021, , 547-581.		0
85	Regulation of Human Thrombin-Activable Fibrinolysis Inhibitor Gene Expression in Megakaryocyte-Like (Dami) and Monocyte/Macrophage- Like (THP-1) Cell Lines. <i>Blood</i> , 2008, 112, 3078-3078.	1.4	0
86	Regulation of the Gene Encoding Human Thrombin-Activable Fibrinolysis Inhibitor by Female Sex Steroids. <i>Blood</i> , 2008, 112, 3077-3077.	1.4	0
87	Exon Skipping and Alternative Splicing of CPB2 mRNA in Multiple Cell Types Results in Variants of TAFI That Are Inactive and Not Secretable. <i>Blood</i> , 2011, 118, 1189-1189.	1.4	0
88	Apolipoprotein(a)-Dependent Inhibition of Pericellular Plasminogen Activation Is Mediated by Specific Cellular Receptors. <i>Blood</i> , 2011, 118, 2236-2236.	1.4	0
89	Lipoprotein (a): Principles from Bench to Bedside. <i>Contemporary Cardiology</i> , 2021, , 363-381.	0.1	0